Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

NMPA Accepts and Grants Priority Review to NDA for Sovleplenib in Primary Immune Thrombocytopenia

January 11th 2024

The China National Medical Products Administration has accepted the NDA seeking approval of sovleplenib in patients with primary immune thrombocytopenia.

Dr Bezerra on the Real-World Efficacy of Brexu-Cel in B-ALL

January 11th 2024

Evandro D. Bezerra, MD, discusses real-world outcomes associated with brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Freeman on Factors Influencing Response to CAR T-Cell Therapy in Hematology

January 11th 2024

Ciara Freeman, MD, PhD, outlines an analysis conducted to identify factors linked to CAR T-cell therapy response in patients with hematologic malignancies.

FDA Grants Fast Track Status to SLS009 for Relapsed/Refractory Acute Myeloid Leukemia

January 10th 2024

The FDA has granted fast track designation to SLS009 for use in patients with relapsed or refractory acute myeloid leukemia.

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

January 10th 2024

Amer Zeidan, MBBS, MHS, presents data from the IMerge phase 3 study on the efficacy of imetelstat in achieving red blood cell transfusion independence across different risk subgroups in patients with lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis-stimulating agents.

Future of Treatment of B-Cell Malignancies

January 10th 2024

Nicole Lamanna, MD, looks ahead at the future of treatment of B-cell malignancies, highlighting exciting therapeutic developments.

Tazemetostat as Third-line and Beyond Therapy for FL

January 10th 2024

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

January 10th 2024

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Asciminib Provides MMR Benefits vs SOC TKIs in Newly Diagnosed Ph+ CML

January 8th 2024

Asciminib demonstrated a favorable safety profile and induced statistically significant and clinically meaningful major molecular response benefits vs standard-of-care TKIs in patients with newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Research Developments Provide Clarity and Raise Further Questions in Myeloma, Myelofibrosis, DLBCL, and MDS

January 5th 2024

Sikander Ailawadhi, MD, discusses characteristics of myelofibrosis that influence decisions between JAK inhibitors, highlights differences between bispecific antibodies to consider when managing diffuse large B-cell lymphoma, and more.

Dr Ip on the Importance of NGS Testing in Hematologic Malignancies

January 5th 2024

Andrew Ip, MD, discusses findings from a study on the use of next-generation sequencing of flow cytometry CD markers and machine learning as a replacement to flow cytometry analysis for the diagnosis of hematologic neoplasms.

Continuity of Care During Maintenance Therapy

January 5th 2024

A discussion about how ensuring continuity of care for patients with AML on maintenance therapy with a focus on how the care team can coordinate to ensure best outcomes.

The Goals of AML Maintenance Therapy

January 5th 2024

Catherine E. Lai, MD, MPH, discusses the goals of maintenance therapy, how to manage treatment-related adverse events, and the impact of treatment on patient’s quality of life.

Dr Hill on the Use of Carfilzomib With R-CHOP in DLBCL

January 4th 2024

Brian T. Hill, MD, PhD, discusses the final results from a phase 1/2 trial of carfilzomib given with R-CHOP in the frontline setting for patients with non-germinal center diffuse large B-cell lymphoma.

Dr Sallman on the Rationale For Investigating Fedratinib in MDS/MPN Overlap Syndromes

January 4th 2024

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.

Ongoing Research on Targeted Therapy in Relapsed/Refractory CLL

January 3rd 2024

A hematologist/oncologist discusses ongoing research on targeted therapy for patients with relapsed/refractory chronic lymphocytic leukemia.

Treatment Sequencing for Patients With B-Cell Malignancies

January 3rd 2024

Comprehensive insights on clinical and patient factors that inform treatment selection and sequencing for patients with B-cell malignancies.

CAR T-cells as Third-line and Beyond Therapy for FL

January 2nd 2024

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Current Treatment Options in Second-line FL

January 2nd 2024

Experts on follicular lymphoma discuss second-line treatment options available for patients.

ASH 2023 Updates on Frontline Therapies in FL

January 2nd 2024

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.